U.S. Markets closed

Exelixis, Inc. (EXEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.77+0.35 (+2.01%)
At close: 04:00PM EST
17.99 +0.22 (+1.24%)
After hours: 04:54PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close17.42
Bid17.30 x 3000
Ask17.78 x 1000
Day's Range17.01 - 17.78
52 Week Range15.50 - 25.77
Avg. Volume2,091,281
Market Cap5.622B
Beta (5Y Monthly)0.88
PE Ratio (TTM)34.84
EPS (TTM)0.51
Earnings DateFeb 08, 2022 - Feb 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.77

    Resonant Capital Advisors, LLC Buys Marqeta Inc, Vanguard Tax-Exempt Bond ETF, iShares National ...

    Investment company Resonant Capital Advisors, LLC (Current Portfolio) buys Marqeta Inc, Vanguard Tax-Exempt Bond ETF, iShares National Muni Bond ETF, Apple Inc, Inc, sells Xilinx Inc, Biogen Inc, Citrix Systems Inc, Exelixis Inc, Citigroup Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Resonant Capital Advisors, LLC.

  • Motley Fool

    5 Value Stocks That Can Make You Richer in 2022

    For more than a decade, growth stocks have been the talk of Wall Street. Since value stocks are profitable and time-tested, they're the perfect place for patient investors to put their money to work. Below are five value stocks that could make you richer in 2022.

  • Business Wire

    Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022

    ALAMEDA, Calif., January 18, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced results for cabozantinib (CABOMETYX®) in combination with immunotherapies in patients with advanced colorectal cancer, including encouraging data from cohort 16 of the phase 1b COSMIC-021 trial of cabozantinib in combination with atezolizumab in patients with metastatic colorectal cancer who were previously treated with fluoropyrimidine-containing chemotherapy. Results from cohort 2 of the phase 2 CAMILLA trial of c